Calliditas Therapeutics AB (publ)
CLTEF · OTC
5/31/2025 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $1,207 | $803 | $229 |
| % Growth | -100% | 50.3% | 250.1% | – |
| Cost of Goods Sold | $0 | $60 | $1 | $0 |
| Gross Profit | -$0 | $1,146 | $75 | $229 |
| % Margin | -55.8% | 95% | 9.4% | 100% |
| R&D Expenses | $0 | $502 | $40 | $40 |
| G&A Expenses | $1,893 | $331 | $25 | $23 |
| SG&A Expenses | $1,893 | $1,061 | $74 | $43 |
| Sales & Mktg Exp. | $0 | $728 | $49 | $20 |
| Other Operating Expenses | $0 | -$43 | -$2 | $671 |
| Operating Expenses | $1,893 | $1,519 | $112 | $754 |
| Operating Income | -$0 | -$373 | -$422 | -$524 |
| % Margin | -1,138.4% | -30.9% | -52.6% | -228.7% |
| Other Income/Exp. Net | $0 | -$84 | $13 | $11 |
| Pre-Tax Income | -$0 | -$457 | -$409 | -$513 |
| Tax Expense | $0 | $9 | $3 | -$4 |
| Net Income | -$0 | -$466 | -$40 | -$55 |
| % Margin | -558.6% | -38.6% | -4.9% | -24.1% |
| EPS | -0.058 | -8.69 | -7.78 | -9.84 |
| % Growth | 99.3% | -11.7% | 20.9% | – |
| EPS Diluted | -0.058 | -8.69 | -7.78 | -9.84 |
| Weighted Avg Shares Out | 16,986 | 54 | 53 | 51 |
| Weighted Avg Shares Out Dil | 16,985 | 54 | 53 | 51 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $3 | $1 |
| Interest Expense | $0 | $44 | $0 | $0 |
| Depreciation & Amortization | $272 | $4 | $0 | $29 |
| EBITDA | -$1,718 | -$386 | -$413 | -$494 |
| % Margin | -9,435,477% | -32% | -51.4% | -215.4% |